1. Empagliflozin and left atrial function in patients with type 2 diabetes mellitus and coronary artery disease: insight from the EMPA-HEART CardioLink-6 randomized clinical trial.
- Author
-
Pourafkari M, Connelly KA, Verma S, Mazer CD, Teoh H, Quan A, Goodman SG, Rai A, Ng MY, Deva DP, Triverio P, Jiminez-Juan L, Yan AT, and Ge Y
- Subjects
- Humans, Male, Female, Middle Aged, Aged, Treatment Outcome, Time Factors, Double-Blind Method, Atrial Remodeling drug effects, Heart Atria physiopathology, Heart Atria drug effects, Heart Atria diagnostic imaging, Glucosides therapeutic use, Glucosides adverse effects, Benzhydryl Compounds therapeutic use, Benzhydryl Compounds adverse effects, Diabetes Mellitus, Type 2 drug therapy, Diabetes Mellitus, Type 2 diagnosis, Diabetes Mellitus, Type 2 physiopathology, Diabetes Mellitus, Type 2 complications, Sodium-Glucose Transporter 2 Inhibitors therapeutic use, Sodium-Glucose Transporter 2 Inhibitors adverse effects, Coronary Artery Disease drug therapy, Coronary Artery Disease physiopathology, Coronary Artery Disease diagnostic imaging, Atrial Function, Left drug effects
- Abstract
Background: Sodium-glucose cotransporter-2 (SGLT2) inhibitors have demonstrated reduction in heart failure outcomes in patients with type 2 diabetes mellitus, although the exact mechanism of benefit remains unclear. Alteration in left atrial (LA) function due to chronic pressure or volume overload is a hallmark of heart failure., Objective: To evaluate the effect of the SGLT2 inhibitor empagliflozin on LA volume and function., Methods: 90 patients with coronary artery disease and type 2 diabetes (T2DM) were randomized to empagliflozin (n = 44) or placebo (n = 46), and underwent cardiac magnetic resonance (CMR) imaging at baseline and after 6 months. The main outcome was change in LA volume; LA function, including active and passive components, was also measured by a blinded reader., Results: At baseline, there was no significant difference in LA volumes between the empagliflozin (indexed maximum LA volume 26.4 ± 8.4mL/m
2 , minimum LA volume 11.1 ± 5.7mL/m2 ) and placebo (indexed maximum LA volume 28.7 ± 8.2mL/m2 , minimum LA volume 12.6 ± 5.0mL/m2 ) groups. After 6 months, changes in LA volumes did not differ with adjusted difference (empagliflozin minus placebo): 0.99 mL/m2 (95% CI: -1.7 to 3.7 mL/m2 ; p = 0.47) for indexed maximum LA volume, and 0.87 mL/m2 (95% CI: -0.9 to 2.6 mL/m2 ; p = 0.32) for indexed minimum LA volume. Changes in total LA emptying fraction were also similar, with between-group adjusted mean difference - 0.01 (95% CI: -0.05 to 0.03, p = 0.59)., Conclusion: SGLT2 inhibition with empagliflozin for 6 months did not have a significant impact on LA volume and function in patients with T2DM and coronary artery disease. (Effects of Empagliflozin on Cardiac Structure in Patients with Type 2 Diabetes [EMPA-HEART]; NCT02998970)., (© 2024. The Author(s).)- Published
- 2024
- Full Text
- View/download PDF